人乳头瘤病毒疫苗的现状
Current status of human papillomavirus vaccines.
作者信息
Kim Kwang Sung, Park Shin Ae, Ko Kyung-Nam, Yi Seokjae, Cho Yang Je
机构信息
Eyegene Inc., Seoul, Korea.
出版信息
Clin Exp Vaccine Res. 2014 Jul;3(2):168-75. doi: 10.7774/cevr.2014.3.2.168. Epub 2014 Jun 20.
Abstract
Cervical cancer is a malignant neoplasm arising from cells that originate in the cervix uteri. It is the second most prevalent cancer among women. It can have several causes; an infection with some type of human papillomavirus (HPV) is the greatest risk factor for cervical cancer. Over 100 types of HPVs have been identified, and more than 40 types of HPVs are typically transmitted through sexual contact and infect the anogenital region. Among these, a number of HPVs types, containing types 16 and 18, are classified as "high-risk" HPVs that can cause cervical cancer. The HPVs vaccine prevents infection with certain species of HPVs associated with the development of cervical cancer, genital warts, and some less common cancers. Two HPVs vaccines are currently on the global market: quadrivalent HPVs vaccine and bivalent HPV vaccine that use virus-like particles as a vaccine antigen. This review discusses the current status of HPVs vaccines on the global market, clinical trials, and the future of HPVs vaccine development.
摘要
宫颈癌是一种起源于子宫颈细胞的恶性肿瘤。它是女性中第二常见的癌症。其发病原因有多种；感染某种类型的人乳头瘤病毒（HPV）是宫颈癌的最大风险因素。已鉴定出100多种HPV类型，其中40多种HPV通常通过性接触传播并感染肛门生殖器区域。在这些类型中，包括16型和18型在内的多种HPV类型被归类为可导致宫颈癌的“高危”HPV。HPV疫苗可预防感染某些与宫颈癌、尖锐湿疣和一些不太常见癌症发生相关的HPV种类。目前全球市场上有两种HPV疫苗：四价HPV疫苗和二价HPV疫苗，它们使用病毒样颗粒作为疫苗抗原。本综述讨论了全球市场上HPV疫苗的现状、临床试验以及HPV疫苗开发的未来。
相似文献
1
Current status of human papillomavirus vaccines.人乳头瘤病毒疫苗的现状
Clin Exp Vaccine Res. 2014 Jul;3(2):168-75. doi: 10.7774/cevr.2014.3.2.168. Epub 2014 Jun 20.
2
Human papilloma virus in oral cancer.口腔癌中的人乳头瘤病毒
J Korean Assoc Oral Maxillofac Surg. 2016 Dec;42(6):327-336. doi: 10.5125/jkaoms.2016.42.6.327. Epub 2016 Dec 27.
3
Ten years of HPV vaccines: State of art and controversies.HPV 疫苗十年：现状与争议。
Crit Rev Oncol Hematol. 2016 Jun;102:65-72. doi: 10.1016/j.critrevonc.2016.03.020. Epub 2016 Apr 2.
4
Genitoanal human papillomavirus infection and associated neoplasias.生殖器肛门人乳头瘤病毒感染及相关肿瘤
Curr Probl Dermatol. 2014;45:98-122. doi: 10.1159/000358423. Epub 2014 Mar 13.
5
Virus-like Particle-Based L2 Vaccines against HPVs: Where Are We Today?基于病毒样颗粒的抗人乳头瘤病毒疫苗：我们如今进展如何？
Viruses. 2019 Dec 23;12(1):18. doi: 10.3390/v12010018.
6
Comparison of different human papillomavirus (HPV) vaccine types and dose schedules for prevention of HPV-related disease in females and males.不同人乳头瘤病毒（HPV）疫苗类型及接种程序对预防女性和男性HPV相关疾病的比较。
Cochrane Database Syst Rev. 2019 Nov 22;2019(11):CD013479. doi: 10.1002/14651858.CD013479.
7
[HPV vaccination and the prevention of genital warts and precancerous lesions-current evidence and evaluation].[人乳头瘤病毒疫苗与生殖器疣及癌前病变的预防——当前证据与评估]
Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz. 2021 May;64(5):590-599. doi: 10.1007/s00103-021-03316-x. Epub 2021 Apr 13.
8
Quadrivalent Human Papillomavirus Vaccine: Recommendations of the Advisory Committee on Immunization Practices (ACIP).四价人乳头瘤病毒疫苗：免疫实践咨询委员会（ACIP）的建议
MMWR Recomm Rep. 2007 Mar 23;56(RR-2):1-24.
9
Quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine (gardasil(®)): a review of its use in the prevention of premalignant anogenital lesions, cervical and anal cancers, and genital warts.四价人乳头瘤病毒（6、11、16、18 型）重组疫苗（佳达修(®)）：用于预防癌前肛门生殖器病变、宫颈和肛门癌以及生殖器疣的用途介绍。
Drugs. 2014 Jul;74(11):1253-83. doi: 10.1007/s40265-014-0255-z.
10
Spotlight on quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine(Gardasil®) in the prevention of premalignant genital lesions, genital cancer, and genital warts in women.重点介绍四价人乳头瘤病毒（6、11、16、18 型）重组疫苗（佳达修®）在预防女性的癌前生殖器病变、生殖器癌和生殖器疣方面的作用。
BioDrugs. 2011 Oct 1;25(5):339-43. doi: 10.2165/11205060-000000000-00000.
引用本文的文献
1
Cervical Cancer Stages, Human Papillomavirus Integration, and Malignant Genetic Mutations: Integrative Analysis of Datasets from Four Different Cohorts.宫颈癌分期、人乳头瘤病毒整合与恶性基因突变：来自四个不同队列数据集的综合分析
Cancers (Basel). 2023 Nov 26;15(23):5595. doi: 10.3390/cancers15235595.
2
Human Papillomavirus 16 DNA Methylation Patterns and Investigation of Integration Status in Head and Neck Cancer Cases.人乳头瘤病毒 16 型 DNA 甲基化模式及头颈部癌症病例中整合状态的研究。
Int J Mol Sci. 2023 Sep 26;24(19):14593. doi: 10.3390/ijms241914593.
3
Peptide Vaccines as Therapeutic and Prophylactic Agents for Female-Specific Cancers: The Current Landscape.肽疫苗作为女性特定癌症的治疗和预防剂：当前现状
Pharmaceuticals (Basel). 2023 Jul 24;16(7):1054. doi: 10.3390/ph16071054.
4
Prevalence and genotype distribution of genital human papillomavirus infection in female sex workers in the world: a systematic review and meta-analysis.全球女性性工作者中生殖器人乳头瘤病毒感染的患病率及基因型分布：一项系统评价与荟萃分析
BMC Public Health. 2020 Sep 25;20(1):1455. doi: 10.1186/s12889-020-09570-z.
5
Therapeutic Cancer Vaccines-T Cell Responses and Epigenetic Modulation.治疗性癌症疫苗 - T 细胞反应与表观遗传调控
Front Immunol. 2019 Jan 25;9:3109. doi: 10.3389/fimmu.2018.03109. eCollection 2018.
6
Antigenic Peptide Prediction From E6 and E7 Oncoproteins of HPV Types 16 and 18 for Therapeutic Vaccine Design Using Immunoinformatics and MD Simulation Analysis.应用免疫信息学和 MD 模拟分析技术从 HPV 型 16 和 18 的 E6 和 E7 癌蛋白预测用于治疗性疫苗设计的抗原肽。
Front Immunol. 2018 Dec 19;9:3000. doi: 10.3389/fimmu.2018.03000. eCollection 2018.
7
Assessing the Importance of Domestic Vaccine Manufacturing Centers: An Overview of Immunization Programs, Vaccine Manufacture, and Distribution.评估国内疫苗生产中心的重要性：免疫计划、疫苗生产和分配概述。
Front Immunol. 2018 Jan 18;9:26. doi: 10.3389/fimmu.2018.00026. eCollection 2018.
8
Human papilloma virus in oral cancer.口腔癌中的人乳头瘤病毒
J Korean Assoc Oral Maxillofac Surg. 2016 Dec;42(6):327-336. doi: 10.5125/jkaoms.2016.42.6.327. Epub 2016 Dec 27.
9
HPV Vaccination: Attitude and Knowledge among German Gynecologists.人乳头瘤病毒疫苗接种：德国妇科医生的态度与知识水平
Geburtshilfe Frauenheilkd. 2016 Oct;76(10):1074-1080. doi: 10.1055/s-0042-112813.
10
Immunodominant T-Cell Epitopes in the VP1 Capsid Protein of Rhinovirus Species A and C.A 型和 C 型鼻病毒 VP1 衣壳蛋白中的免疫显性 T 细胞表位
J Virol. 2016 Nov 14;90(23):10459-10471. doi: 10.1128/JVI.01701-16. Print 2016 Dec 1.
本文引用的文献
1
Characterization of the structure and immunostimulatory activity of a vaccine adjuvant, de-O-acylated lipooligosaccharide.一种疫苗佐剂——去O-酰化脂寡糖的结构及免疫刺激活性表征
PLoS One. 2014 Jan 22;9(1):e85838. doi: 10.1371/journal.pone.0085838. eCollection 2014.
2
Combination of adjuvants: the future of vaccine design.佐剂联合：疫苗设计的未来。
Expert Rev Vaccines. 2013 Jul;12(7):733-46. doi: 10.1586/14760584.2013.811185.
3
Review of Gardasil.加德西（宫颈癌疫苗）综述
J Vaccines Vaccin. 2010 Nov 23;1(107). doi: 10.4172/2157-7560.1000107.
4
Perceptions and acceptability of HPV vaccination among parents of young adolescents: a multicenter national survey in China.中国青少年父母对 HPV 疫苗接种的认知和可接受性：一项多中心全国性调查。
Vaccine. 2013 Jul 11;31(32):3244-9. doi: 10.1016/j.vaccine.2013.05.046. Epub 2013 May 24.
5
Developing Countries Vaccine Manufacturers Network (DCVMN): engaging to step up for vaccine discovery and access. Meeting report 2012.发展中国家疫苗生产商网络（DCVMN）：参与加强疫苗研发和获取力度。会议报告 2012 年。
Vaccine. 2013 Jun 28;31(31):3111-5. doi: 10.1016/j.vaccine.2013.04.082. Epub 2013 May 15.
6
A randomized, observer-blinded immunogenicity trial of Cervarix(®) and Gardasil(®) Human Papillomavirus vaccines in 12-15 year old girls.一项比较佳达修（Gardasil(®)）和卉妍康（Cervarix(®)）人乳头瘤病毒疫苗在 12-15 岁少女中免疫原性的随机、观察者设盲临床试验
PLoS One. 2013 May 1;8(5):e61825. doi: 10.1371/journal.pone.0061825. Print 2013.
7
Human papillomavirus vaccine introduction--the first five years.人乳头瘤病毒疫苗接种——头五年。
Vaccine. 2012 Nov 20;30 Suppl 5:F139-48. doi: 10.1016/j.vaccine.2012.05.039.
8
Comparison of the immune responses to the CIA06-adjuvanted human papillomavirus L1 VLP vaccine with those against the licensed HPV vaccine Cervarix™ in mice.比较 CIA06 佐剂的人乳头瘤病毒 L1 VLP 疫苗与已上市的 HPV 疫苗 Cervarix™ 在小鼠中的免疫反应。
Vaccine. 2012 Jun 13;30(28):4127-34. doi: 10.1016/j.vaccine.2012.04.079. Epub 2012 May 1.
9
Sustained immunogenicity and efficacy of the HPV-16/18 AS04-adjuvanted vaccine: up to 8.4 years of follow-up.HPV-16/18 AS04 佐剂疫苗的持续免疫原性和效力：长达 8.4 年的随访。
Hum Vaccin Immunother. 2012 Mar;8(3):390-7. doi: 10.4161/hv.18865. Epub 2012 Feb 13.
10
Recommendations on the use of quadrivalent human papillomavirus vaccine in males--Advisory Committee on Immunization Practices (ACIP), 2011.关于男性使用四价人乳头瘤病毒（HPV）疫苗的建议——免疫实践咨询委员会（ACIP），2011 年。
MMWR Morb Mortal Wkly Rep. 2011 Dec 23;60(50):1705-8.
Zotero 插件